Premium
The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.
Author(s) -
Lennard MS,
Jackson PR,
Freestone S,
Tucker GT,
Ramsay LE,
Woods HF
Publication year - 1984
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1984.tb02403.x
Subject(s) - debrisoquine , pharmacokinetics , pharmacodynamics , propranolol , pharmacology , hydroxylation , chemistry , medicine , metabolism , cyp2d6 , biochemistry , cytochrome p450 , enzyme
The pharmacokinetics and pharmacodynamics of propranolol (80 mg by mouth) were studied in seven extensive and four poor metabolisers of debrisoquine. Evidence for impairment of the 4′‐hydroxylation of propranolol was found in poor metabolisers. However, no significant difference was detected in the oral clearance of unchanged drug between the two groups of debrisoquine oxidation phenotypes. Poor metabolisers of debrisoquine did not experience more intense or more prolonged beta‐ adrenoceptor blockade than extensive metabolisers of debrisoquine.